GABA-A receptor; alpha-2/beta-3/gamma-2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA-A receptor; alpha-2/beta-3/gamma-2 as ChEMBL target CHEMBL2094130, mapped to UniProt P18507. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why GABA-A receptor; alpha-2/beta-3/gamma-2 matters
GABA-A receptor; alpha-2/beta-3/gamma-2 is reviewed as Gamma-aminobutyric acid receptor subunit gamma-2 (UniProt P18507); the current evidence base includes 8 approved drugs, 624 compounds, and 96 assays, with lead potency reaching pChEMBL 10.5.
Gamma-aminobutyric acid receptor subunit gamma-2 Sequence length is 475 aa.
Review this target as GABA-A receptor; alpha-2/beta-3/gamma-2, mapped to UniProt P18507. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit gamma-2. Sequence length is 475 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 8 approved drugs, 624 compounds, and 96 assays for this target. The dominant activity type is KI. CHEMBL3144849 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL3144849 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why GABA-A receptor; alpha-2/beta-3/gamma-2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P18507, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3144849
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL3144696
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL3144697
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL19732
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL3144841
|
10.0 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZOLPIDEM
CHEMBL911
|
1992 |
|
|
FLUMAZENIL
CHEMBL407
|
1991 |
|
|
TRIAZOLAM
CHEMBL646
|
1978 |
|
|
DIAZEPAM
CHEMBL12
|
1963 |
|
|
CHLORDIAZEPOXIDE
CHEMBL451
|
1960 |
|
|
FLUNITRAZEPAM
CHEMBL13280
|
— |